What PCOS Questions Should You Ask Your Doctor?

Why a Prepared Question List Matters

Most PCOS appointments last 15 to 20 minutes. Without a focused agenda, conversations drift toward whichever symptom feels most urgent that day, and metabolic screening or mental health questions get skipped entirely. A 2017 survey published in the Journal of Clinical Endocrinology & Metabolism found that 33.6% of women with PCOS reported dissatisfaction with the information they received at diagnosis [1]. Structured questions change that dynamic.

The Diagnostic Delay Problem

The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS confirmed that diagnostic delays remain a global problem, with women visiting an average of 3.1 healthcare professionals before receiving a diagnosis [2]. Each visit without a clear answer adds cost, frustration, and lost time for early metabolic intervention. Arriving with specific questions about Rotterdam criteria, androgen panels, and ultrasound findings signals to your clinician that you expect a thorough workup.

What the Evidence Says About Patient Engagement

A 2020 study in Human Reproduction (N=1,385) showed that women who reported higher health literacy scores were significantly more likely to receive guideline-concordant PCOS care [3]. Knowing which labs to request and which screenings are overdue is not about challenging your doctor. It is about collaborative care that follows current evidence.

Questions About Diagnosis and Lab Work

The right opening question is straightforward: "Do I meet the Rotterdam criteria, and which two of the three features apply to me?" The Rotterdam consensus requires at least two of three findings: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound [4]. Knowing your specific phenotype (there are four) shapes every treatment decision that follows.

Essential Labs to Request

Ask your doctor to order or review these specific tests:

• Total and free testosterone (drawn in the early morning, fasting)
• DHEA-S to rule out adrenal androgen excess
• 17-hydroxyprogesterone to exclude non-classic congenital adrenal hyperplasia
• TSH and free T4 to rule out thyroid dysfunction mimicking PCOS
• Prolactin to exclude hyperprolactinemia
• AMH (anti-Müllerian hormone), which the 2023 guideline now recognizes as a diagnostic alternative to ultrasound in adults [2]

A 2019 meta-analysis in Fertility and Sterility found that serum AMH >4.7 ng/mL had 82.8% sensitivity and 79.4% specificity for polycystic ovarian morphology, making it a reasonable substitute when transvaginal ultrasound is declined or unavailable [5].

Questions About Ultrasound Findings

If your clinician orders a pelvic ultrasound, ask: "Are you using the updated threshold of 20 or more follicles per ovary, or the older 12-follicle cutoff?" The 2023 guideline raised the threshold from 12 to 20 follicles (on probes with frequency ≥8 MHz) to reduce overdiagnosis with modern imaging technology [2]. This single question can prevent a false-positive PCOS label in younger women with physiologically normal multifollicular ovaries.

Questions About Insulin Resistance and Metabolic Risk

Insulin resistance affects 50 to 80% of women with PCOS and is present across all BMI categories, not only in those with higher body weight [6]. Your metabolic questions should start here: "Have I been screened with a 75-gram oral glucose tolerance test, not just a fasting glucose?"

Why Fasting Glucose Alone Is Not Enough

The Endocrine Society's 2013 Clinical Practice Guideline recommends a 75-g OGTT for all women with PCOS at diagnosis, noting that fasting glucose alone misses up to 38% of cases of impaired glucose tolerance in this population [7]. A normal fasting glucose does not rule out postprandial hyperinsulinemia, which drives many PCOS symptoms including weight gain, acanthosis nigricans, and androgen overproduction.

Lipid and Cardiovascular Screening

Ask: "When was my last fasting lipid panel, and have you calculated my 10-year cardiovascular risk?" Women with PCOS have a 2-fold increased risk of coronary artery events compared to age-matched controls, according to a 2020 meta-analysis in the European Heart Journal (N=118,002) [8]. The 2023 guideline recommends lipid screening at diagnosis and repeat testing every one to two years depending on results [2].

Additional metabolic questions to bring:

| Question | Why It Matters | |---|---| | "Should I be screened for obstructive sleep apnea?" | OSA prevalence in PCOS is 5- to 30-fold higher than in weight-matched controls [9] | | "Is my blood pressure being tracked at every visit?" | Hypertension risk is elevated independent of BMI | | "Should I get a liver panel for fatty liver screening?" | NAFLD prevalence in PCOS ranges from 34 to 70% [10] |

Questions About Treatment Options

The best opening treatment question is: "What is the primary goal of my treatment right now, and which medication matches that goal?" Treatment in PCOS is symptom-directed. There is no single drug that addresses every feature.

For Menstrual Irregularity

Combined oral contraceptives (COCs) remain first-line for cycle regulation and androgen suppression per the 2023 guideline [2]. Ask: "Which COC formulation are you recommending, and does it contain an anti-androgenic progestin like drospirenone or cyproterone acetate?" The choice of progestin component matters. A Cochrane review (2020) of 10 trials found that COCs containing cyproterone acetate reduced hirsutism scores more than those with levonorgestrel, though both regulated cycles effectively [11].

For Insulin Resistance

Metformin is the most studied insulin-sensitizing agent in PCOS. A 2019 Cochrane review of 42 RCTs (N=4,052) found that metformin reduced fasting insulin by 1.6 µIU/mL and lowered BMI by 0.53 kg/m² compared with placebo, though the clinical significance of these differences varied by phenotype [12]. Ask: "Am I a candidate for metformin based on my glucose tolerance results, and would you start at 500 mg or titrate to 1,500 to 2,000 mg?"

For women who cannot tolerate metformin's gastrointestinal side effects, extended-release formulations reduce adverse events. Ask about this specifically.

For Hirsutism and Acne

Spironolactone at 50 to 100 mg daily is the most commonly prescribed anti-androgen in the United States for PCOS-related hirsutism. Ask: "What is the expected timeline before I see results?" Most studies show a minimum of six months for meaningful hair reduction [2]. Topical eflornithine (Vaniqa) may provide faster visible improvement for facial hirsutism, and can be combined with spironolactone.

Questions About Fertility and Family Planning

If pregnancy is a goal, the single most important question is: "Are you recommending letrozole or clomiphene citrate as first-line ovulation induction?" The answer should be letrozole. The NICHD-funded Pregnancy in Polycystic Ovary Syndrome (PPCOS II) trial (N=750) demonstrated that letrozole produced a cumulative live birth rate of 27.5% compared to 19.1% with clomiphene citrate (P=0.007) [13].

Timing and Monitoring

Ask: "Will you monitor my follicular response with serial ultrasounds during ovulation induction?" Unmonitored cycles carry a higher risk of multiple gestations. The American Society for Reproductive Medicine recommends cycle monitoring to reduce this risk, particularly for gonadotropin-based protocols.

Weight and Ovulation Recovery

Dr. Robert Norman, a reproductive endocrinologist who co-authored the 2023 international PCOS guideline, has stated: "A 5 to 10 percent weight reduction can restore ovulatory cycles in a significant proportion of women with PCOS, and should be attempted before pharmacologic ovulation induction when time permits" [2].

Ask: "Given my age and ovarian reserve, do I have time for a lifestyle-first approach, or should we start medication now?" The answer depends on your age, duration of infertility, and partner factors. Do not accept a vague "just lose some weight" without a specific timeline and backup plan.

Preconception Metabolic Optimization

A 2021 cohort study in The Lancet Diabetes & Endocrinology (N=9,081) found that women with PCOS had a 3-fold higher risk of gestational diabetes mellitus (GDM) compared to controls [14]. Ask: "Should I have a preconception OGTT, and do you recommend metformin continuation during pregnancy to reduce GDM risk?" The evidence on metformin for GDM prevention in PCOS is mixed, with the PregMet2 trial (N=487) showing no significant reduction in GDM incidence (RR 0.97, 95% CI 0.75 to 1.25) [15]. Your clinician should discuss this nuance.

Questions About Weight Management

Weight-related conversations in PCOS deserve more precision than "eat less, move more." Start with: "Is my weight gain primarily driven by insulin resistance, and does that change the type of intervention you recommend?"

Structured Lifestyle Intervention

The 2023 guideline recommends structured lifestyle intervention as first-line for weight management in PCOS, targeting 5 to 10% body weight loss with a combination of caloric reduction (500 to 750 kcal/day deficit), 150 minutes per week of moderate-intensity exercise, and behavioral support [2]. Ask: "Can you refer me to a dietitian experienced with PCOS, and should my macronutrient distribution be adjusted for insulin resistance?"

A 2021 RCT in Obesity (N=87) compared a Mediterranean-style diet to a standard low-fat diet in women with PCOS over 12 weeks and found greater improvements in insulin sensitivity (HOMA-IR reduction of 1.1 vs 0.4, P=0.03) with the Mediterranean approach [16].

Pharmacologic Options for Weight

Ask: "Am I a candidate for GLP-1 receptor agonist therapy for weight management?" Liraglutide 3.0 mg (Saxenda) and semaglutide 2.4 mg (Wegovy) are FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. PCOS with insulin resistance qualifies. A 2024 systematic review of 10 trials (N=668) found that GLP-1 receptor agonists in women with PCOS reduced body weight by a mean of 5.7 kg and HOMA-IR by 1.4 compared to placebo or metformin [17].

Questions About Mental Health

PCOS carries a mental health burden that is often underaddressed. A meta-analysis in Human Reproduction Update (2019) found that women with PCOS had a 3.78-fold higher odds of depression and a 5.62-fold higher odds of anxiety compared to controls [18]. Ask your doctor directly: "Are you screening me for depression and anxiety as part of my PCOS care?"

Screening Tools and Referrals

The 2023 guideline recommends that all clinicians managing PCOS screen for anxiety and depression at diagnosis and at regular intervals using validated tools such as the PHQ-9 and GAD-7 [2]. If your clinician is not doing this, ask: "Can you administer the PHQ-9 today, and can you refer me to a psychologist or psychiatrist if my score is elevated?"

Dr. Helena Teede, lead author of the 2023 international PCOS guideline, has stated: "Mental health screening is not optional in PCOS care. The evidence is clear that psychological distress is a core feature, not a secondary complaint" [2].

Body Image and Disordered Eating

Ask: "Should I be screened for disordered eating before starting a caloric-deficit diet?" Women with PCOS have a 3- to 4-fold higher prevalence of eating disorders compared to the general population [19]. Beginning a restrictive diet without screening can worsen existing disordered eating patterns.

Questions About Long-Term Monitoring

PCOS is a lifelong condition. The metabolic risks do not disappear after menopause. Ask: "What is my monitoring schedule for the next five years, and what screenings should I expect at each visit?"

A Practical Monitoring Checklist

| Test | Frequency | |---|---| | 75-g OGTT or HbA1c | Every 1 to 3 years (annually if additional risk factors) | | Fasting lipid panel | Every 1 to 2 years | | Blood pressure | Every visit | | Depression/anxiety screen (PHQ-9, GAD-7) | Annually at minimum | | Endometrial assessment | If amenorrhea exceeds 90 days without progestogen withdrawal | | Weight, waist circumference | Every visit |

Endometrial protection is often overlooked. Chronic anovulation without progesterone opposition raises the risk of endometrial hyperplasia. The Endocrine Society recommends progestogen withdrawal (either cyclic progestogen or a COC) if spontaneous menses do not occur within 90 days [7]. Ask: "How are you protecting my endometrium if I am not having regular periods?"

Women with PCOS have a 2.7-fold increased risk of endometrial cancer compared to the general population, according to a meta-analysis of 11 studies [20]. This question is not hypothetical.